WILEX AG announces change on the Executive Management Board
| PDF Download
Munich, Germany, 2 June 2016 – WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today announced that Professor Andreas Pahl has been appointed to the company’s Executive Management Board to serve as the new Head of Research and Development. Professor Pahl will take over this capacity with immediate effect.
Professor Andreas Pahl has worked successfully as Chief Scientific Officer and member of the executive management of WILEX’s subsidiary Heidelberg Pharma GmbH since September 2012, and can look back on 20 years’ experience in research and higher education. Prior to his position at Heidelberg Pharma, he spent four years as Head of Late Pharmacology at Nycomed and Takeda Pharmaceuticals. After graduating in chemistry from the University of Berlin, he spent several years lecturing at TU Berlin and the University of Erlangen-Nuremberg (FAU), at which he was also appointed Professor of Pharmacology and Toxicology. Professor Pahl will continue to perform his teaching duties at FAU.
Professor Christof Hettich, Chairman of the Supervisory Board of WILEX AG, commented: “Over the years, we have come to know Andreas Pahl not only as a competent research scientist with a strong set of leadership skills but also as a valuable and greatly appreciated contact for partners in our ADC business.”
Dr Jan Schmidt-Brand, CFO and Spokesman of the Executive Management Board, added: “We warmly welcome Andreas Pahl’s appointment: it gives us a Head of Research and Development who is able to draw on many years of experience in R&D and who is not only thoroughly familiar with our day-to-day business but is deeply committed to powerfully driving this business forward.”
Professor Andreas Pahl said: “I am very pleased to accept the position of CSO at WILEX AG and am aware of the great responsibility this entails. Although acquiring investors and partners for our technology while securing funding is a constant challenge, this is balanced by the huge opportunities presented once we provide proof of clinical effectiveness, as well as good safety and tolerability in patients. As in the past, I will continue to work with great enthusiasm on the development and utilisation of our ATAC technology.”
About WILEX and Heidelberg Pharma
WILEX AG is a biopharmaceutical company which discontinued all clinical development activities at its Munich site and now exercises a holding function as the Group parent. Research and development focus on the operations of its subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances the development of the innovative platform technology for antibody drug conjugates (ADC technology) and provides pre-clinical drug discovery and development services. WILEX has the diagnostic and therapeutic drug candidates REDECTANE® and RENCAREX®, which are available for out-licensing and further development in Phase III for external partners. WILEX is listed at the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at http://www.wilex.com/.
Tel.: +49 (0)89-41 31 38-29
Grillparzerstr. 18, 81675 Munich
MC Services AG
Katja Arnold (CIRO)
Executive Director & Partner
Tel.: +49-89-210 228-40
Mobil: +49 160 9360 3022
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward- looking statements to reflect future events or developments.